Vertex Pharma DEF 14A: Executive Compensation Details
Ticker: VRTX · Form: DEF 14A · Filed: Apr 3, 2025 · CIK: 875320
Sentiment: neutral
Topics: executive-compensation, proxy-statement, governance
Related Tickers: VRTX
TL;DR
Vertex Pharma's 2025 DEF 14A is out, detailing exec pay and equity awards for 2024. Focus on Reshma Kewalramani's compensation.
AI Summary
Vertex Pharmaceuticals Inc. filed its DEF 14A on April 3, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including awards granted to Reshma Kewalramani, a member of the company. Specific financial data related to equity awards and their valuation for the covered year is presented.
Why It Matters
This filing provides transparency into how Vertex Pharmaceuticals compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) detailing executive compensation and corporate governance, not indicating new or unusual risks.
Key Numbers
- 20250403 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 2024-12-31 — Fiscal Year End (The period covered by the compensation details in this filing.)
Key Players & Entities
- VERTEX PHARMACEUTICALS INC / MA (company) — Filer
- Reshma Kewalramani (person) — Executive Member
- 0000875320 (company) — Central Index Key
- 000-19319 (company) — SEC File Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, including the election of directors and executive compensation.
Who is Reshma Kewalramani and what is her role at Vertex Pharmaceuticals?
Reshma Kewalramani is listed as a Member of Vertex Pharmaceuticals and her compensation details are included in the filing for the fiscal year 2024.
What specific financial information is typically detailed in a DEF 14A filing regarding executive compensation?
DEF 14A filings detail various forms of executive compensation, including base salary, bonuses, stock awards, option awards, and other benefits, along with the valuation of these awards.
When was this specific DEF 14A filing submitted to the SEC?
This DEF 14A filing for Vertex Pharmaceuticals Inc. was submitted to the SEC on April 3, 2025.
What is the fiscal year end for Vertex Pharmaceuticals as reported in this filing?
The fiscal year end for Vertex Pharmaceuticals Inc. as reported in this filing is December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 3, 2025 by Reshma Kewalramani regarding VERTEX PHARMACEUTICALS INC / MA (VRTX).